title: Targeting NF-κB and HIF-1 pathways for the treatment of cancer: part I.
abstract: The process of chronic inflammation is a common link which connects different kinds of environmental pollutants and infections with tumorigenesis. Transcription factor NF-κB is a common final target for many inflammatory and cell proliferation pathways, independent of the source of stimuli (e.g., cytokines, growth factors, environmental carcinogens, radiation, hypoxia, bacteria, and viruses). Over-activation of NF-κB has been confirmed in many tumors, resulting in worse prognosis for patient survival. Therefore, inhibition of cellular pathways for NF-κB activation is nowadays considered as a promising anti-cancer therapy and is extensively studied in clinical trials, or even has been adopted as an approved therapy in some kinds of cancer.
authors.affiliation: "Polish Mother's Health Center" Research Institute, Lodz, Poland. jrwil@post.pl
authors.forename: Jacek
authors.initials: J
authors.lastname: Wilczynski
authors.forename: Markus
authors.initials: M
authors.lastname: Duechler
authors.forename: Malgorzata
authors.initials: M
authors.lastname: Czyz
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology; D001897:Boronic Acids / Q000494:pharmacology / Q000627:therapeutic use; D000069286:Bortezomib; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D002986:Clinical Trials as Topic; D016207:Cytokines / Q000378:metabolism; D005786:Gene Expression Regulation; D006801:Humans; D051793:Hypoxia-Inducible Factor 1 / Q000037:antagonists & inhibitors / Q000378:metabolism; D007249:Inflammation / Q000188:drug therapy / Q000235:genetics / Q000503:physiopathology*; D051379:Mice; D008954:Models, Biological; D016328:NF-kappa B / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism; D009369:Neoplasms / Q000188:drug therapy / Q000378:metabolism / Q000503:physiopathology; D011719:Pyrazines / Q000494:pharmacology / Q000627:therapeutic use; D015398:Signal Transduction; D014157:Transcription Factors / Q000235:genetics / Q000378:metabolism; D016159:Tumor Suppressor Protein p53 / Q000819:agonists
chemical_list: D000970:Antineoplastic Agents; D001897:Boronic Acids; D016207:Cytokines; D051793:Hypoxia-Inducible Factor 1; D016328:NF-kappa B; D011719:Pyrazines; D014157:Transcription Factors; D016159:Tumor Suppressor Protein p53; D000069286:Bortezomib